Skip to content
★ Sign in to follow
SB

Samuel Backenroth

Ohr Pharmaceutical IncNotable Labs, Ltd.
Total declarations
24
Companies
2
▲ Purchases (22 ops.)
€75k
▼ Sales (0 ops.)
—

Latest filing published 18 Apr 2023 for Notable Labs, Ltd..

Filing timeline

BuySale
Samuel Backenroth

Insider track record

Disclosed buys
22
Disclosed sells
0
Signal history

Closed purchases

Market purchases
22

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Samuel Backenroth: trading record in brief

This profile gathers the share dealings of Samuel Backenroth across 2 companies, led by Ohr Pharmaceutical Inc and Notable Labs, Ltd. The record holds 24 filings, for trades running from 6 February 2015 to 31 March 2023.

The open-market record is one-sided, with 22 purchases worth €75k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant and 1 option exercise.

Half of the purchases are above €474 and half below. On 7 out of 21 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 18 April 2023, the filings show an option exercise in Notable Labs, Ltd. The last insider purchase was made public on 4 May 2020, 2,379 days ago. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Samuel Backenroth

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations24 total
  • ◇
    Chief Financial OfficerExecutivesNotable Labs, Ltd.
    0SEC
    525,000 sharesOrdinary SharesSEC:0001493152-23-012789:0
  • ▲
    CFO, Treasurer & SecretaryExecutivesOhr Pharmaceutical Inc
    6,000 USD45SEC
    1,000 shares@ US$6.00100.0% of flowCommon StockSEC:0001104659-20-056066:0
    Canonical exit: 29 Jul 2020 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    50,000 USD47SEC
    71,429 shares@ US$0.7071.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-17-002049:0
    Canonical exit: 9 Jul 2017 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    29 USD37SEC
    10 shares@ US$2.890.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005871:0
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    23 USD37SEC
    8 shares@ US$2.880.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005871:1
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    1,292 USD37SEC
    450 shares@ US$2.871.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005871:2
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    5,112 USD38SEC
    1,800 shares@ US$2.846.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005871:3
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    542 USD37SEC
    200 shares@ US$2.710.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005871:4
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    526 USD19SEC
    163 shares@ US$3.230.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:0
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    35 USD19SEC
    11 shares@ US$3.220.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:1
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    591 USD19SEC
    184 shares@ US$3.210.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:2
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    173 USD19SEC
    54 shares@ US$3.200.2% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:3
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    485 USD19SEC
    152 shares@ US$3.190.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:4
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    611 USD19SEC
    192 shares@ US$3.180.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:5
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    2,644 USD19SEC
    834 shares@ US$3.173.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:6
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    1,198 USD19SEC
    379 shares@ US$3.161.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:7
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    580 USD19SEC
    184 shares@ US$3.150.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:8
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    135 USD19SEC
    43 shares@ US$3.140.2% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:9
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    304 USD19SEC
    97 shares@ US$3.130.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:10
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    34 USD19SEC
    11 shares@ US$3.130.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:11
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    509 USD19SEC
    163 shares@ US$3.120.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:12
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    103 USD19SEC
    33 shares@ US$3.110.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005678:13
    Canonical exit: 21 Aug 2016 (T+90)
  • ◆
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    0SEC
    130,000 sharesCommon Stock, par value $0.0001 per shareSEC:0001387131-16-003869:0
  • ▲
    Chief Financial OfficerExecutivesOhr Pharmaceutical Inc
    10,125 USD0SEC
    1,500 shares@ US$6.75Common Stock, par value $0.0001 per shareSEC:0001387131-15-000444:0
    Canonical exit: 7 May 2015 (T+90)

24 of 24 declarations